HUE030206T2 - Új EP4 agonisták - Google Patents

Új EP4 agonisták Download PDF

Info

Publication number
HUE030206T2
HUE030206T2 HUE11753372A HUE11753372A HUE030206T2 HU E030206 T2 HUE030206 T2 HU E030206T2 HU E11753372 A HUE11753372 A HU E11753372A HU E11753372 A HUE11753372 A HU E11753372A HU E030206 T2 HUE030206 T2 HU E030206T2
Authority
HU
Hungary
Prior art keywords
disease
group
compound
medicament
agonist
Prior art date
Application number
HUE11753372A
Other languages
English (en)
Inventor
Takahiko Murata
Masahiro Amakawa
Shin Teradaira
Yasushi Matsumura
Katsuhiko Konishi
Original Assignee
Kaken Pharma Co Ltd
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd, Asahi Glass Co Ltd filed Critical Kaken Pharma Co Ltd
Publication of HUE030206T2 publication Critical patent/HUE030206T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (5)

  1. Uj BIN- âgoïiistàk Szabad&bsts igéaypotnok j. Gyógyszer egy m%nunbctcgség: egy szív- és érrendszeri betegség, egy szívbetegé egy vi betegség, egy szembetegség, egy vesebetegség, eg> «^betegség, egy csotstbetegscg, egy rsearológs-ai feÄ m Míbeteg^g, calvities. kopaszság, cervieaUs érési íeísdeílenessög vagy egy haitass rendellenesség snegetozesébosi vagy kezeléseken történő atkatmazásra.* aboi s2 srnas««betegség izomsorvatlâssid járó lateral sdsrosís, sclerosis .mdi&iex». Sjogrén-sztnötérdt, drsönmtaM arthritis, systsarás htptts «ryèématosus, írdtszpíaníádot követé kitükones, attdte, systernás gyuilacíási válasz .sdsdcomä, szeps-sis, hernophagocyta swMrdM, stateoiag: sag vámos sziadtkote, 'bv^;ég#|? tializE sotab tebepo saetv működési zavar, sokk vagy psodaEs, és alsói a gyógyszer hatóatryagkém egy EP4 agonisiát tartalmaz, sssdy i ; 1 ;
    . , , ..... . , ,.·:ΐ»/V ce.v esveeea láncú i~3 széníUomos kepteta, a«ot %> és 1." egymástól; fgaactlsöiti kidœ&amp;àas&amp;r»* """*'" w* «a#«, * r Martom. iv«s « W «**»«“ a““0,>0B> A“altólesoi'on' «Λ»!»«, talógonavom tak^k^rt »gv « «««**«<* *** ~· A 0ö|í}'sSjSj· ujj I. íjlésiyposti: S£kFkííi ^kï!m#,âs&amp;k lŐKft ^ ! &amp;s^P'sæôr.à*ï:i. vagy 2. 4v ,4 gyógyszer as ! 4:. igénypontok bàmedyske saeriaù alkalmazásra, ahol E" làfegàÎaixîîn. 5 A gpgysAXm. 44 igénypontok bámteiysko szenou alkalmazásra. ahol R meXcsopost, és 14 htd» sogEt^m. 4 A#èpW »2'4í>. íjgéaypostöfeBámeiysks s^ntóialksimaxásísg*k&amp;ft"' nv^mevrtesoport 7. I ..igéô^Mf'Sàæriôîî ^IMmááásjfö^Aöi jfe: ^óttiéMPft> ft" aiarogeaatom, ás R gíádscsaport. g A gyôgyszéi m 1. jgéttypom $g$gin&amp; •lökalmÄsa.-iiiM·^ -hi4fqgiln!^n% Mt mtküesogeíA es 14 metiksopoR. e ;4 gyógyír as I. igétsypoot sapant! albkígKisM, afel az EÍ4 agonEfe 44p)A^A4ö%®4<> :|lÉ41i4RS}:44i:ém34-<a54©ÍM}A''peat@aá!-'a'hidn3x:i4-oxa'4444aoí-bic4io|4:..yö|0ktaa-,>'' :iUdéa:l~4E^íSsól441)feásy vagy agy.gÂ'àaaÂI.^^^&amp;até^ jg: A gyógyír m L j&amp;Wjùtomn# Mïïmàstz ahol sä EM apnte 4-j M.K1 $^Rf>R- ;R)"°' 1I4iä|4 ^etmäö!4-ii )PÄg vagy H. a gyógyszer as. \ igénypont szerinti aikalmazasra. ahoi nz EP4 agonists 4-!(ZM iSAEÄ'Mft' p' s H. >Rs4S)"â~hidio\t“pontonti!'7*hidfoxi"2"Oxa“4.4'diíluor-nitíkiois.^.Ejs'h-vyiî' tildén}** ! -ttctntzokMí Jbuu'm, vágj· egy gjdgtuvzahbg ei fogadható atyja, IX A gyógyszer as 1-1.1 igénypoatób bármelyiké:Sszerinív aümimszasrs. shot a *4- betegség vagy szívbetegség arterioseterosss.. m&amp;m pestem, sppőanáfeitS' hiÄrktds» ägyvA.Ja ält«l Γ . .., ' 4 , . , <...... ,: ., < , · . (ΐ._ ...,., c..s!vs<..^grtoid vérzés állal okozott agyi îv^ûeUcîïÊxîe^g. agy* sníadíius anal okav.oíi &amp;&amp;>*. *í>Uí:>-<*v-- okozod agyi rendellenesség, maps tüddsÄa vinwöMlA pedfétíás attests elzáródás vagy vgy pen-Eriss keringési zavar által okozott szimptósna.
  2. 13. A gyógyszer as 1-11, %#sypo«t#··:bta#ÍP szgági alkalinassara,Ml a «áft úidoadridés, íhdofíbmsis, smphysasa. ρ·
  3. 14. A gyógyszer as J-Η. igénypontok bármelyike szériád aikaiaiasássa, ahol. a szembetegség is utam kóma vagy saráéban íebcgb magas vérayoróás.
  4. 16, A gyógyszer az 1 11. igénypontok bánoelyike szerinti alkalmazásra, abol a yesebotegség glemerM on spóráig diaóeieszes «epbropth^ IgA aepbrogatbis vagy vess rschemm-repertuziés sérülés.
    16. A gyógyszer as Ml. igénypontok háHndyike szermíi alkalmazásra, aboi a májbetegség hepatitis, hepatopatWa vagy -máj iseimmMreperibzios sérülés. 1/. á gyógyszer as 1--11. igóoypfMtok bármelyike szeried alkalmazásra, ahöl a esoótbelegség osteoporosis, ósóo béres vagy7 egy ostootomiát követő maiét utáöi felépülési feg.
  5. 18. Â gyógyszer as A J 1. igénypontok bánselyike szerinti alktlma-zásm, ahol a «earologiaí betegség Megsejt sikál ás, .19.. A gyógyaser az Ai J. igénypontok bármely rke szerinti alkalmazásra, ahol a bőrbetegség nyomásos teke K vagy seb.
HUE11753372A 2010-03-08 2011-03-08 Új EP4 agonisták HUE030206T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010051127 2010-03-08
JP2010246208 2010-11-02

Publications (1)

Publication Number Publication Date
HUE030206T2 true HUE030206T2 (hu) 2017-04-28

Family

ID=44563514

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11753372A HUE030206T2 (hu) 2010-03-08 2011-03-08 Új EP4 agonisták

Country Status (16)

Country Link
EP (1) EP2545917B1 (hu)
JP (1) JP5734952B2 (hu)
KR (1) KR101760970B1 (hu)
CN (1) CN102917703B (hu)
AU (1) AU2011225259B2 (hu)
BR (1) BR112012022632B1 (hu)
CA (1) CA2792403C (hu)
DK (1) DK2545917T3 (hu)
ES (1) ES2593229T3 (hu)
HU (1) HUE030206T2 (hu)
MX (1) MX2012010483A (hu)
PL (1) PL2545917T3 (hu)
PT (1) PT2545917T (hu)
RU (1) RU2564414C2 (hu)
TW (1) TWI555744B (hu)
WO (1) WO2011111714A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2884582C (en) * 2012-10-26 2020-10-27 Asahi Glass Co Ltd Method for producing difluoro ester compound
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
CN111278464A (zh) * 2017-08-31 2020-06-12 柏林夏瑞蒂医科大学 用于防止妥协性患者中肌肉骨骼损伤愈合不良的免疫调节
JP7233087B2 (ja) * 2019-03-18 2023-03-06 公立大学法人横浜市立大学 抗動脈硬化剤
HU231350B1 (hu) 2019-12-18 2023-01-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt Eljárás királis prosztaglandin-enol intermedier előállítására, és az eljárásban hasznos köztitermék vegyületek
TW202400150A (zh) 2022-05-16 2024-01-01 日商Ａｇｃ股份有限公司 IL-6及/或IL-1β抑制劑
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788209A (fr) 1971-09-01 1973-02-28 Pfizer Derives tetrazoyliques des prostaglandines naturelles
DE2405255A1 (de) 1973-02-08 1974-08-15 Sandoz Ag Neue tetrazolderivate und verfahren zu ihrer herstellung
KR970002877B1 (ko) * 1987-07-17 1997-03-12 더 누트라스웨트 캄파니 고성능 감미제
DE69502517T2 (de) * 1994-02-17 1998-10-01 Asahi Glass Co Ltd Difluorprostacycline, Zwischenprodukte und Verfahren zu deren Herstellung
JP3719524B2 (ja) 1994-03-17 2005-11-24 旭硝子株式会社 ジハロゲン化プロスタサイクリン類の製造方法
JP3769738B2 (ja) * 1994-04-11 2006-04-26 旭硝子株式会社 ジフルオロプロスタサイクリン類
JPH08217772A (ja) 1995-02-13 1996-08-27 Asahi Glass Co Ltd ジフルオロ置換ビニルエーテル類の製造方法
TW401408B (en) * 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
JP3598611B2 (ja) 1995-10-17 2004-12-08 旭硝子株式会社 ジフルオロ化合物の製造方法
EP0795331B1 (en) * 1995-11-14 2002-04-10 Toray Industries, Inc. Ocular depressor
TW416953B (en) * 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
AUPO440696A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. New use
US6340693B1 (en) * 1997-03-14 2002-01-22 Toray Industries, Inc. Protective agent for nervous system structural cells
IT1299191B1 (it) * 1998-06-23 2000-02-29 Sigma Tau Healthscience Spa Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
WO2000024727A1 (en) 1998-10-23 2000-05-04 Toray Industries, Inc. 5,6,7-TRINOR-4,8-INTER-m-PHENYLENE PGI2 DERIVATIVE AND DRUGS CONTAINING THE SAME
OA12533A (en) * 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003103664A1 (en) 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
EP1988087A1 (en) 2007-03-28 2008-11-05 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of autoimmune diseases
EP2343292B1 (en) * 2008-09-10 2014-08-06 Asahi Glass Company, Limited Novel prostaglandin i2 derivative

Also Published As

Publication number Publication date
PT2545917T (pt) 2016-10-25
EP2545917A1 (en) 2013-01-16
MX2012010483A (es) 2012-10-09
WO2011111714A1 (ja) 2011-09-15
DK2545917T3 (en) 2016-11-14
EP2545917A4 (en) 2014-09-10
BR112012022632B1 (pt) 2020-03-31
BR112012022632A2 (pt) 2017-10-03
AU2011225259A1 (en) 2012-10-11
KR20130018753A (ko) 2013-02-25
JP5734952B2 (ja) 2015-06-17
CA2792403A1 (en) 2011-09-15
RU2012142653A (ru) 2014-04-20
TWI555744B (zh) 2016-11-01
ES2593229T3 (es) 2016-12-07
JPWO2011111714A1 (ja) 2013-06-27
CN102917703A (zh) 2013-02-06
CA2792403C (en) 2018-06-12
CN102917703B (zh) 2015-08-19
AU2011225259B2 (en) 2015-07-23
PL2545917T3 (pl) 2017-01-31
EP2545917B1 (en) 2016-08-03
TW201139421A (en) 2011-11-16
KR101760970B1 (ko) 2017-07-24
RU2564414C2 (ru) 2015-09-27

Similar Documents

Publication Publication Date Title
US8691857B2 (en) EP4 agonist
DK2545917T3 (en) NEW EP4 AGONIST.
JP6475624B2 (ja) 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
KR20130115311A (ko) S1p 수용체의 조절제
CN111138422B (zh) 一种用于防治红斑狼疮的药物及其制备方法
JP3600630B2 (ja) プロスタグランジン誘導体およびその使用